分红方面，和邦生物A股上市后累计派现12.05亿元。近三年，累计派现5.53亿元。 机构持仓方面，截止2025年9月30日，和邦生物十大流通股东中，鹏华中证细分化工产业主题ETF联接A （014942）位居第四大流通股东，持股9278.78万股，为新进股东。南方中证500ETF（510500）位居第 五大流通股东，持股9008.99万股，相比上期减少218.44万股。香港中央结算有限公司位居第六大流通股 东，持股8928.26万股，相比上期增加1609.08万股。光大保德信信用添益债券A类（360013）位居第九 大流通股东，持股3300.96万股，为新进股东。中欧红利优享灵活配置混合A（004814）位居第十大流通 股东，持股2459.99万股，为新进股东。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 融资方面，和邦生物当日融资买入1.70亿元。当前融资余额6.64亿元，占流通市值的2.61%，融资余额 超过 ...

中化新网讯 近日，在安卡拉举行的高层战略合作理事会会议上，土耳其与乌兹别克斯坦签署了多项协 议，旨在将双边全面战略伙伴关系拓展至能源与工业领域。 此次会谈将能源明确列为双方致力于深化的关键合作领域之一。在"中间走廊"等区域互联互通项目的背 景下，两国在能源资源开发、化工产品贸易及产业投资方面的协同有望进一步增强，共同塑造欧亚大陆 内部的能源与经济合作新格局。会议成果直接涉及能源化工板块。双方签署了涵盖采矿项目合作的双边 协议，并同意扩展在核安全领域的协作。这表明两国合作正从一般贸易向资源开发与高端能源技术等产 业链上游延伸。 经济与贸易数据进一步揭示了两国在能源化工领域的紧密联系与互补性。目前土耳其和乌兹别克斯坦双 边贸易额已接近30亿美元，目标为50亿美元。乌兹别克斯坦对土耳其的主要出口商品包括矿物产品、塑 料和橡胶;而土耳其对乌兹别克斯坦的出口则以化学产品、塑料和橡胶、机械设备为主。这一贸易结构 显示乌兹别克斯坦主要提供原材料及初级产品，而土耳其则出口附加值更高的制成品与生产设备。 ...

Core Viewpoint - The stock of Hebang Biotechnology has shown a positive trend with a year-to-date increase of 10.62%, reflecting investor interest and market activity [1]. Group 1: Stock Performance - As of February 11, the stock price of Hebang Biotechnology reached 2.50 CNY per share, with a trading volume of 1.59 billion CNY and a market capitalization of 22.079 billion CNY [1]. - The stock has experienced a 0.81% increase over the last five trading days, a 14.68% increase over the last 20 days, and a 2.46% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 59.5468 million CNY on January 28, accounting for 14.52% of total trading volume [1]. Group 2: Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province, and specializes in the manufacturing of pesticides, fine chemicals, and various glass products [2]. - The company's revenue composition includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [2]. - The company operates within the basic chemical industry, specifically in the agricultural chemical sector, and is involved in concepts such as chemical raw materials and phosphate chemicals [2]. Group 3: Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion CNY, a decrease of 13.02% year-on-year, and a net profit attributable to shareholders of 93.1085 million CNY, down 57.93% year-on-year [2]. - The company has distributed a total of 1.205 billion CNY in dividends since its A-share listing, with 553 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, with an average of 44,939 shares held per shareholder, an increase of 2.03% [2]. - Notable institutional shareholders include Penghua CSI Sub-Sector Chemical Industry Theme ETF and Southern CSI 500 ETF, with significant holdings and changes in share quantities [3].

Core Viewpoint - The EU-India free trade agreement is seen as a significant breakthrough, providing the EU access to a large international market, which is welcomed by both the political and business sectors in Ireland [1]. Group 1: Economic Impact - The agreement will reduce tariffs on 99% of goods exported from the EU to India, benefiting Irish whiskey and certain food exports [1]. - In 2024, Ireland's total goods exports to India are projected to be slightly below €500 million, with machinery, pharmaceuticals, and chemicals being the main categories [1]. Group 2: Industry Specifics - The Irish Whiskey Association anticipates that the agreement will increase the sales of Irish whiskey in the Indian market, promoting diversification within the industry [1]. - Sales of Irish whiskey in India are expected to exceed 700,000 cases in 2024, representing a year-on-year growth of 57.5% and a 900% increase compared to 2020 [1].

1月30日，和邦生物跌5.24%，成交额13.51亿元。两融数据显示，当日和邦生物获融资买入额1.12亿 元，融资偿还1.51亿元，融资净买入-3902.42万元。截至1月30日，和邦生物融资融券余额合计6.41亿 元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融资方面，和邦生物当日融资买入1.12亿元。当前融资余额6.32亿元，占流通市值的2.83%，融资余额 超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 截至9月30日，和邦生物股东户数19.65万，较上期减少1.99%；人均流通股44939股，较上期增加 2.03%。2025年1月-9月，和邦生物实现营业收入59.27亿元，同比减少13.02%；归母净利润9310.85万 元，同比减少57.93%。 分红方面，和邦生物A股上市后累计派现12.05亿元。近三年，累计派现5.53亿元。 机构持仓方面，截止2025年9月30日，和邦生物十大流通股东中，鹏华中证细分化 ...

交银智选星光混合(FOF-LOF)A（501210）基金经理为刘兵。 截至发稿，刘兵累计任职时间4年153天，现任基金资产总规模16.37亿元，任职期间最佳基金回报 53.13%， 任职期间最差基金回报-12.13%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月22日，和邦生物涨5.35%，截至发稿，报2.56元/股，成交2.25亿元，换手率1.03%，总市值226.09亿 元。和邦生物股价已经连续3天上涨，区间累计涨幅9.46%。 资料显示，四川和邦生物科技股份有限公司位于四川省乐山市五通桥区牛华镇沔坝村，成立日期2002年 8月1日，上市日期2012年7月31日，公司主营业务涉及农药及农药中间体制造、精细化工产品制造、智 能玻璃、特种玻璃制造及纯碱、氯化铵制造及盐矿、磷矿的开发。主营业务收入构成为：化学产品 85.89%，光伏玻璃及其他产品17.61%，矿产品6.74%，其他业务5.02%。 从基金十大重仓股角度 数据显示，交银施罗德基金 ...

Core Viewpoint - Tian De Chemical (00609) has announced the acquisition of a 49% equity stake in Weifang Zhongying Chemical Co., Ltd. for RMB 88 million, aiming to enhance its position in the fine chemical industry and improve operational efficiency [1] Group 1: Acquisition Details - The buyer, Weifang Binhai Petrochemical Co., Ltd., is a wholly-owned subsidiary of the company [1] - The seller, Zhejiang Zhongshan Chemical Group Co., Ltd., has agreed to sell the stake, which will make the target company a wholly-owned subsidiary of the company upon completion [1] Group 2: Strategic Rationale - The acquisition is part of the company's strategy to strengthen its position in the fine chemical sector amid significant operational challenges in China's manufacturing industry [1] - The company aims to streamline decision-making processes and align the target company's operations with its long-term growth strategy through full integration [1] Group 3: Growth Opportunities - By fully integrating the target company, the group plans to leverage its strong capabilities, competitive advantages, industry expertise, and existing customer relationships to pursue additional growth opportunities [1] - This move supports the company's commitment to disciplined expansion and operational excellence, ultimately creating sustainable value for shareholders [1]

Core Viewpoint - Tian De Chemical (00609) has announced the acquisition of a 49% equity stake in Weifang Zhongying Chemical Co., Ltd. for RMB 88 million, which will make the target company a wholly-owned subsidiary, enhancing the company's position in the fine chemicals industry [1] Group 1: Acquisition Details - The buyer, Weifang Binhai Petrochemical Co., Ltd., is an indirect wholly-owned subsidiary of Tian De Chemical [1] - The transaction is set to be completed by December 29, 2025 [1] - The target company primarily engages in the research, development, manufacturing, and sales of chemical products [1] Group 2: Strategic Rationale - The acquisition is part of the company's strategy to strengthen its position in the fine chemicals sector amid significant operational challenges in China's manufacturing industry [1] - The company aims to enhance operational efficiency and streamline decision-making processes through full ownership of the target company [1] - By integrating the target company, the group plans to leverage its strengths, competitive advantages, industry expertise, and existing customer relationships to pursue additional growth opportunities [1] Group 3: Commitment to Shareholders - The move supports the company's commitment to disciplined expansion and operational excellence, aiming to create sustainable value for shareholders [1]

Core Viewpoint - The stock of Hebang Biotechnology has shown fluctuations with a recent increase of 2.37%, while the company faces a decline in revenue and profit year-on-year [1][2]. Financial Performance - As of September 30, 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a decrease of 13.02% year-on-year, and a net profit attributable to shareholders of 93.11 million yuan, down 57.93% year-on-year [2]. - The company has cumulatively distributed 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the past three years [3]. Stock Market Activity - On November 25, the stock price reached 2.16 yuan per share, with a trading volume of 289 million yuan and a turnover rate of 1.54%, resulting in a total market capitalization of 19.076 billion yuan [1]. - The stock has increased by 5.88% year-to-date, but has seen a decline of 8.09% over the last five trading days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 1.99% to 196,500, with an average of 44,939 circulating shares per person, an increase of 2.03% [2]. - Notable institutional shareholders include Penghua CSI Sub-Industry Chemical Theme ETF and Southern CSI 500 ETF, with significant holdings [3].

Core Viewpoint - The stock of Hebang Biotechnology has shown fluctuations with a recent increase of 2.15%, while the company has experienced a year-to-date stock price increase of 16.67% despite a decline in net profit and revenue for the first nine months of 2025 [1][2]. Group 1: Stock Performance - As of November 20, Hebang Biotechnology's stock price reached 2.38 yuan per share, with a trading volume of 2.16 billion yuan and a turnover rate of 1.04%, resulting in a total market capitalization of 21.019 billion yuan [1]. - The stock has seen a year-to-date increase of 16.67%, a decline of 1.24% over the last five trading days, a rise of 12.26% over the last 20 days, and a 24.61% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on October 9, where it recorded a net purchase of 50.2212 million yuan [1]. Group 2: Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, reflecting a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 931.085 million yuan, down 57.93% year-on-year [2]. - The company has distributed a total of 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the past three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, with an average of 44,939 circulating shares per shareholder, an increase of 2.03% [2]. - The top ten circulating shareholders include new entrants such as Penghua Zhongzheng Segmented Chemical Industry Theme ETF and other institutional investors, indicating a shift in shareholder composition [3].